Tirzepatide vs Semaglutide: Which Is More Effective for Weight Loss?
A clinical comparison of tirzepatide (Zepbound/Mounjaro) and semaglutide (Wegovy/Ozempic) for weight loss, based on the SURMOUNT-5 trial and real-world evidence.
Medically Reviewed
Reviewed by Dr. James Chen, MD, PhD, FACE on March 29, 2026
Our medical review process ensures clinical accuracy and patient safety.
Two injectable medications now dominate the obesity treatment landscape: tirzepatide (Zepbound) and semaglutide (Wegovy). Both belong to the GLP-1 drug class, both require weekly injections, and both produce meaningful weight loss — yet the clinical evidence consistently shows they are not equal. A landmark 2025 head-to-head trial published in the New England Journal of Medicine settled the question with the most rigorous data available, and the answer has significant implications for patients and prescribers alike.
This article breaks down what the science says about tirzepatide vs semaglutide for weight loss, how their mechanisms differ, who each drug is best suited for, and what real-world outcomes look like.
How These Drugs Work: GLP-1 vs Dual GIP/GLP-1 Agonism
Semaglutide is a GLP-1 receptor agonist. It mimics glucagon-like peptide-1, a gut hormone that reduces appetite, slows gastric emptying, and increases insulin secretion in a glucose-dependent manner. Wegovy (2.4 mg/week) is the weight-loss–approved formulation; Ozempic (0.5–2 mg/week) is approved for type 2 diabetes but widely used off-label for obesity.
Tirzepatide is a dual GIP/GLP-1 receptor agonist — a single molecule that activates both GLP-1 and glucose-dependent insulinotropic polypeptide (GIP) receptors. GIP works synergistically with GLP-1 to amplify satiety signals and enhance fat metabolism. Zepbound (2.5–15 mg/week) is approved for chronic weight management; Mounjaro (2.5–15 mg/week) carries the diabetes indication.
This dual mechanism is the pharmacological basis for tirzepatide's stronger efficacy profile.
Head-to-Head Evidence: The SURMOUNT-5 Trial
The most definitive comparison to date came from SURMOUNT-5, a phase 3b open-label randomized controlled trial published in the New England Journal of Medicine in May 2025.
Evidence: "The mean percentage change in body weight at week 72 was −20.2% with tirzepatide and −13.7% with semaglutide — a difference of −6.5 percentage points (95% CI, −7.9 to −5.1; P<0.001)." — Jastreboff AM, et al. N Engl J Med. 2025. DOI: 10.1056/NEJMoa2416394
Study design: 751 adults with obesity (BMI ≥30) and no type 2 diabetes were randomized 1:1 to the maximum tolerated dose of tirzepatide (10 or 15 mg/week) or semaglutide (1.7 or 2.4 mg/week) for 72 weeks. This was a true head-to-head comparison using the drugs as they are prescribed in clinical practice.
Response Rate Thresholds
| Weight Loss Threshold | Tirzepatide | Semaglutide |
|---|---|---|
| ≥10% body weight | 81.6% | 60.5% |
| ≥15% body weight | 64.6% | 40.1% |
| ≥20% body weight | 48.4% | 27.3% |
| ≥25% body weight | 31.6% | 16.1% |
| ≥30% body weight | 19.7% | 6.9% |
The magnitude of the difference is striking at the extreme end: nearly 1 in 5 tirzepatide patients lost 30% or more of their body weight, compared to fewer than 1 in 14 on semaglutide.
Monotherapy Benchmarks: What Each Drug Achieves Alone
To understand where the head-to-head gap comes from, it helps to review each drug's pivotal trial data.
Semaglutide: STEP-1 Trial
Evidence: "The mean change in body weight was −14.9% with semaglutide 2.4 mg versus −2.4% with placebo at 68 weeks (treatment difference −12.4 percentage points, 95% CI −13.4 to −11.5; P<0.001)." — Wilding JPH, et al. N Engl J Med. 2021. DOI: 10.1056/NEJMoa2032183
STEP-1 enrolled 1,961 adults with obesity without type 2 diabetes. Semaglutide 2.4 mg produced ~14.9% weight loss — roughly twice the response seen with older weight-loss medications — establishing it as a transformative therapy at the time of its approval.
Tirzepatide: SURMOUNT-1 Trial
Evidence: "Tirzepatide 15 mg produced a mean weight reduction of 22.5% from baseline at 72 weeks, compared with 2.4% for placebo (P<0.001 for all doses vs. placebo)." — Jastreboff AM, et al. N Engl J Med. 2022. DOI: 10.1056/NEJMoa2206038
SURMOUNT-1 enrolled 2,539 adults with obesity. Even the lowest dose (5 mg) produced 16.0% weight loss, with 15 mg reaching 22.5% — a level approaching bariatric surgery outcomes for a subset of patients.
Real-World Evidence: Clinical Practice Outcomes
RCTs represent ideal conditions. Real-world data from clinical practice reveals whether the advantage holds when patient populations are more heterogeneous and adherence is variable.
Evidence: "In adults with overweight or obesity, tirzepatide use was associated with significantly greater weight loss than semaglutide at all time points: −2.4% at 3 months, −4.3% at 6 months, and −6.9% at 12 months (P<0.001 for all)." — Sh M Anupam, et al. JAMA Intern Med. 2024. DOI: 10.1001/jamainternmed.2024.2525
This propensity-matched cohort study of 18,386 adults found that tirzepatide patients were 1.76× more likely to lose ≥5%, 2.54× more likely to lose ≥10%, and 3.24× more likely to lose ≥15% of body weight compared to those on semaglutide. Rates of gastrointestinal adverse events were similar between groups.
Side Effects: How the Drugs Compare
Both drugs share a similar GI side effect profile driven by their shared GLP-1 mechanism:
| Side Effect | Tirzepatide | Semaglutide |
|---|---|---|
| Nausea | 31–45% | 44% |
| Diarrhea | 20–30% | 31% |
| Constipation | 11–17% | 24% |
| Vomiting | 13–23% | 25% |
| Discontinuation (GI) | ~5–7% | ~5–8% |
SURMOUNT-5 found no significant difference in serious adverse events between the two drugs. Both carry the same boxed warning regarding thyroid C-cell tumors (a risk observed in rodents) and are contraindicated in patients with a personal or family history of medullary thyroid carcinoma or MEN2.
Key Differences
- Injection volume: Tirzepatide uses an auto-injector pen with a smaller delivery volume; both are once-weekly subcutaneous injections.
- Dose escalation: Tirzepatide starts at 2.5 mg and increases in 2.5 mg increments every 4 weeks. Semaglutide starts at 0.25 mg and escalates more slowly over 16–20 weeks.
- Muscle mass: Emerging data suggests both drugs may reduce lean mass alongside fat; resistance exercise is recommended with either agent to mitigate this.
Who Should Choose Which Drug?
Consider tirzepatide when:
- Higher absolute weight loss is the primary goal (≥20% target)
- Previous semaglutide therapy produced suboptimal results
- Cardiovascular risk reduction is a priority (emerging SELECT-analogous data)
- Patient is willing to accept potentially faster dose escalation
Consider semaglutide when:
- Patient has previously tolerated semaglutide well (for type 2 diabetes)
- Insurance coverage strongly favors semaglutide
- Generic or compounded semaglutide access is a cost consideration
- Oral formulation (Rybelsus) is preferred (no equivalent for tirzepatide yet)
Cost and access
Both medications carry list prices in the $1,000–$1,400/month range without insurance. Coverage remains inconsistent: some plans cover one but not the other. Manufacturer savings programs (Lilly Savings Card for Zepbound; Novo Nordisk's program for Wegovy) can significantly reduce out-of-pocket costs for eligible patients. See our guide on insurance coverage for weight loss drugs for more detail.
Key Takeaways
- Tirzepatide produces approximately 6–7% more weight loss than semaglutide in direct head-to-head comparison (SURMOUNT-5, NEJM 2025).
- At the highest doses, tirzepatide achieves ~20% mean body weight reduction versus ~14% with semaglutide.
- Real-world data mirrors RCT findings: tirzepatide patients are significantly more likely to reach all weight loss thresholds.
- Both drugs share a similar GI side effect profile; neither has a meaningful safety advantage over the other for most patients.
- For patients who can access and afford either drug, tirzepatide's dual GIP/GLP-1 mechanism confers a clinically meaningful efficacy advantage.
References
Jastreboff AM, et al. Tirzepatide as Compared with Semaglutide for the Treatment of Obesity. N Engl J Med. 2025. DOI: 10.1056/NEJMoa2416394
Jastreboff AM, et al. Tirzepatide Once Weekly for the Treatment of Obesity (SURMOUNT-1). N Engl J Med. 2022;387(3):205-216. DOI: 10.1056/NEJMoa2206038
Wilding JPH, et al. Once-Weekly Semaglutide in Adults with Overweight or Obesity (STEP-1). N Engl J Med. 2021;384(11):989-1002. DOI: 10.1056/NEJMoa2032183
Anupam S, et al. Semaglutide vs Tirzepatide for Weight Loss in Adults With Overweight or Obesity. JAMA Intern Med. 2024;184(9):1056-1064. DOI: 10.1001/jamainternmed.2024.2525
Last updated: 2026-03-29 Medical review: Dr. James Chen, MD, PhD, FACE
Tags
Written By
Dr. Sarah Mitchell
Medical Director, MD, FACP
Dr. Sarah Mitchell is a board-certified internist specializing in metabolic medicine and weight management. With over 15 years of clinical experience, she has helped thousands of patients achieve sustainable weight loss through evidence-based approaches.
Medical Reviewer
Dr. James Chen
Endocrinologist, MD, PhD, FACE
Dr. James Chen is a fellowship-trained endocrinologist with expertise in diabetes, metabolism, and hormone-related weight disorders. His research on GLP-1 receptor agonists has been published in leading medical journals.
Editorial Standards
This article follows our strict editorial guidelines. All content is based on peer-reviewed research and reviewed by medical professionals. This information is for educational purposes only — always consult your healthcare provider before making medical decisions.